sub:assertion {
  d:DB02546 v:identifier "DB02546" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB02546" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB02546> ;
    dv:drugbank-id "DB02546" , "EXPT02902" ;
    dv:x-atc <http://bio2rdf.org/atc:L01XX38> ;
    dv:x-bindingdb <http://bio2rdf.org/bindingdb:19149> ;
    dv:x-cas <http://bio2rdf.org/cas:149647-78-9> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:5120> ;
    dv:x-ndc <http://bio2rdf.org/ndc:0006-0568-40> ;
    dv:x-pdb <http://bio2rdf.org/pdb:SHH> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA164748224> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:5311> ;
    dv:x-pubchemsubstance <http://bio2rdf.org/pubchem.substance:46508989> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Vorinostat> ;
    dct:description "Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors.  A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs. [Wikipedia]"@en ;
    dct:identifier "drugbank:DB02546" ;
    dct:title "Vorinostat"@en ;
    a dv:Drug ;
    rdfs:label "Vorinostat [drugbank:DB02546]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB02546> , <http://www.drugs.com/cdi/vorinostat.html> , <http://www.rxlist.com/cgi/generic/zolinza.htm> .
}